Cleared Traditional

K812542 - POLAROID INSTANT ENDOCAMERA (FDA 510(k) Clearance)

Class I Radiology device.

K812542 · Polaroid Corp. · Radiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Oct 1981
Decision
45d
Days
Class 1
Risk

K812542 is an FDA 510(k) clearance for the POLAROID INSTANT ENDOCAMERA. Classified as Accessories, Photographic, For Endoscope (exclude Light Sources) (product code FEM), Class I - General Controls.

Submitted by Polaroid Corp. (Mchenry, US). The FDA issued a Cleared decision on October 19, 1981 after a review of 45 days - a notably fast clearance cycle.

This device falls under the Radiology FDA review panel, regulated under 21 CFR 876.1500 - the FDA radiology and imaging software oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Polaroid Corp. devices

Submission Details

510(k) Number K812542 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received September 04, 1981
Decision Date October 19, 1981
Days to Decision 45 days
Submission Type Traditional
Review Panel Radiology (RA)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
62d faster than avg
Panel avg: 107d · This submission: 45d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code FEM Accessories, Photographic, For Endoscope (exclude Light Sources)
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 876.1500
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.